Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 6

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 6
---
4 Warrants were sold on a combined
basis for consideration of $1.175 for one share and a November 2024 Warrant. The exercise price of the November 2024 Warrants is $1.05
per share. One of the November 2024 Purchasers was our Chief Executive Officer, who purchased 42,553 shares and November 2024 Warrants
to purchase 42,553 shares, or the Affiliate Securities, at the same price and upon the same terms as the other November 2024 Purchasers.

The
November 2024 Warrants were immediately exercisable upon issuance and will expire five years following the date of issuance. The November
2024 Warrants contain standard adjustments to the exercise price including for stock splits, stock dividends and reorganizations. In
lieu of making the cash payment otherwise contemplated to be made upon exercise in payment of the aggregate exercise price, the holder
may, in the event the shares underlying the November 2024 Warrants are not registered under the Securities Act, elect instead to receive
upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth
in the November 2024 Warrants. Under the terms of the November 2024 Warrants, a holder (together with its affiliates) may not exercise
any portion of its November 2024 Warrant to the extent that the holder would beneficially own more than the Beneficial Ownership Limitation,
except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the Beneficial Ownership Limitation,
provided that the Beneficial Ownership Limitation in no event exceeds 19.99%.

Paulson
served as the exclusive placement agent for the issuance and sale of the securities. As compensation for such placement agent services,
we paid Paulson an aggregate cash fee equal to 7.0% of the gross proceeds received by us from the offering (excluding the Affiliate Securities),
and a non-accountable expense of $25,000. As additional compensation to Paulson, we issued to the Paulson (or its designees) a warrant,
or the November 2024 Placement Agent Warrants, to purchase an aggregate of 124,212 shares at an exercise price per share equal to $1.3125
per share. The November 2024 Placement Agent Warrants are exercisable six months from the date of issuance and expire on the fifth anniversary
of the issue date.